Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France ; volume:34 ; number:4 ; day:16 ; month:2 ; year:2016 ; pages:363-391 ; date:4.2016
PharmacoEconomics ; 34, Heft 4 (16.2.2016), 363-391, 4.2016
- Urheber
-
Druais, Sylvain
- Beteiligte Personen und Organisationen
-
Doutriaux, Agathe
Cognet, Magali
Godet, Annabelle
Lancon, Christophe
Lévy, Pierre
Samalin, Ludovic
Guillon, Pascal
SpringerLink (Online service)
- DOI
-
10.1007/s40273-015-0348-x
- URN
-
urn:nbn:de:1111-2016032045857
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Druais, Sylvain
- Doutriaux, Agathe
- Cognet, Magali
- Godet, Annabelle
- Lancon, Christophe
- Lévy, Pierre
- Samalin, Ludovic
- Guillon, Pascal
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis